[go: up one dir, main page]

MX2025006992A - Antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r) - Google Patents

Antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r)

Info

Publication number
MX2025006992A
MX2025006992A MX2025006992A MX2025006992A MX2025006992A MX 2025006992 A MX2025006992 A MX 2025006992A MX 2025006992 A MX2025006992 A MX 2025006992A MX 2025006992 A MX2025006992 A MX 2025006992A MX 2025006992 A MX2025006992 A MX 2025006992A
Authority
MX
Mexico
Prior art keywords
mc2r
receptor
crystalline
antagonist
melanocortin
Prior art date
Application number
MX2025006992A
Other languages
English (en)
Inventor
Yuxin Zhao
Jayachandra P Reddy
Colin M Kelly
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of MX2025006992A publication Critical patent/MX2025006992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas de N-[(3S)-1-azabiciclo[2.2.2]octan-3-il]-6-(2-etoxifenil)-3-[(2R)-2-etil-4-[1-(trifluorometil)-ciclobutancarbonil]piperazin-1-il]piridin-2-carboxamida y métodos para su preparación. Tales formas de N-[(3S)-1-azabiciclo[2.2.2]octan-3-il]-6-(2-etoxifenil)-3-[(2R)-2-etil-4-[1-(trifluorometil)-ciclobutancarbonil]piperazin-1-il]piridin-2-carboxamida son útiles en la preparación de composiciones farmacéuticas para el tratamiento de enfermedades o condiciones que podrían beneficiarse de la administración de un compuesto antagonista del receptor de melanocortina subtipo 2 (MC2R).
MX2025006992A 2022-12-16 2025-06-13 Antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r) MX2025006992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263387884P 2022-12-16 2022-12-16
PCT/US2023/084242 WO2024130091A1 (en) 2022-12-16 2023-12-15 Crystalline melanocortin subtype-2 receptor (mc2r) antagonist

Publications (1)

Publication Number Publication Date
MX2025006992A true MX2025006992A (es) 2025-09-02

Family

ID=91486101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025006992A MX2025006992A (es) 2022-12-16 2025-06-13 Antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r)

Country Status (11)

Country Link
US (1) US20240208963A1 (es)
EP (1) EP4634176A1 (es)
KR (1) KR20250117804A (es)
CN (1) CN120344523A (es)
AU (1) AU2023395880A1 (es)
CL (1) CL2025001713A1 (es)
CO (1) CO2025009622A2 (es)
IL (1) IL321291A (es)
MX (1) MX2025006992A (es)
TW (1) TW202430167A (es)
WO (1) WO2024130091A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211644A1 (en) 2021-03-19 2022-09-22 Christine FERRARA-COOK Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2024242979A1 (en) * 2023-05-19 2024-11-28 Crinetics Pharmaceuticals, Inc. Compositions and methods for the treatment of congenital adrenal hyperplasia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236699A1 (en) * 2018-06-05 2019-12-12 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
CA3211644A1 (en) * 2021-03-19 2022-09-22 Christine FERRARA-COOK Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Also Published As

Publication number Publication date
US20240208963A1 (en) 2024-06-27
CL2025001713A1 (es) 2025-08-08
TW202430167A (zh) 2024-08-01
CN120344523A (zh) 2025-07-18
KR20250117804A (ko) 2025-08-05
CO2025009622A2 (es) 2025-08-08
WO2024130091A1 (en) 2024-06-20
AU2023395880A1 (en) 2025-06-19
EP4634176A1 (en) 2025-10-22
IL321291A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
MX2025006992A (es) Antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
JP2009510171A5 (es)
ZA202304064B (en) Quinoline cgas antagonist compounds
RU2010124593A (ru) Противовоспалительные композиции и комбинации
JP2018090566A5 (es)
Khodaie-Ardakani et al. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study
MX2024006064A (es) Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
Cavaye et al. NK1 receptor antagonists versus other antiemetics in the prevention of postoperative nausea and vomiting following laparoscopic surgical procedures: a systematic review and meta-analysis
MX2024010674A (es) Compuestos de quinolina antagonistas de cgas.
MX2025000641A (es) Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado
CN109078189A (zh) 含有蛋白激酶抑制剂与白藜芦醇的组合物
Fortun et al. Posaconazole salvage therapy: The Posifi study
WO2022204344A3 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
WO2023034645A3 (en) Asymmetric allyl tryptamines
Smith et al. An overview of nausea/vomiting in palliative medicine
Hitoshi et al. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases
CA3153302A1 (en) Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain
BRPI0418610A (pt) métodos para tratar ou prevenir, e para controlar um distúrbio do sistema nervoso central, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um distúrbio do sistema nervoso central, e, composição farmacêutica
Castagnola et al. Antifungal prophylaxis in children receiving antineoplastic chemotherapy
Bollen et al. Adult dolutegravir 50 mg film-coated tablets in children living with HIV weighing 20 to< 25 kg
RU2010125711A (ru) Меквитазин для лечения или предотвращения патологий, в которых задействованы н4 рецепторы гистамина
Shetti et al. Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic